A peak into Cancer Crosslinks

World-leading translational cancer research entered Oslo Cancer Cluster Innovation Park during this one-day conference and created a buzz.

Once a year, the Kaare Norum auditorium is filled with cancer experts, researchers, clinicians, and students. Numerous questions arose from an engaged audience during the scientific presentations and in the mingling areas during the breaks.

The best way of experiencing Cancer Crosslinks, meeting fellow cancer professionals, and exchanging experiences, was of course to participate in person. If you were prevented from attending, we have made this accessible picture special of the day.

Oslo Cancer Cluster EU advisor Marine Jeanmougin during one of the breaks.

“The Cancer Crosslinks educational series aims to make the latest translational research in Oncology and Haematology accessible to Norwegian researchers and clinicians. It is such a privilege to contribute to shaping the scientific programme and to dialogue with world-leading experts.”

Marine Jeanmougin, Oslo Cancer Cluster’s EU advisor and part of the scientific Cancer Crosslinks 2024 team.

Prof. Sonja Loges from Heidelberg University was the keynote speaker. She gave the audience an overview of the personalized oncology landscape in Germany, among other interesting topics.

On 25 January, around 300 people participated in scientific sessions during the 16th edition of the conference Cancer Crosslinks, themed “Bridging innovations to improve clinical outcomes for cancer patients”.

This edition covered a range of topics, including targeted treatments and immunotherapies, the role of new technologies in oncology, and the impact of tumour heterogeneity on clinical outcome.

Dr. Leo Rasche from University Hospital Würzburg was one of the speakers at Cancer Crosslinks 2024. He also participated actively in the audience.

The audience gained insights, for instance into how the composition of the microbiome can affect response to immunotherapy, and in the case of myeloma; how a single dormant cancer cell can cause a patient to relapse after 10 years of remission. Participants also got an overview of the personalized oncology landscape in Germany and heard how AI-driven innovations can change the way clinical studies are run.

Dr. Lisa Derosa from Institut Gustave Roussy and moderator Dr. Marte Grønli Cameron from Sørlandet Hospital on stage during the event.

To get an overview of the speakers and moderators of the day, and their research, please read this article.
Read about the sponsors behind Cancer Crosslinks in this article.

Be part of the buzzing conversation next year. We are already planning for Cancer Crosslinks 2025!

There will be a new opportunity to be present in person next January when we arrange the 17th Cancer Crosslinks during the 10th anniversary of Oslo Cancer Cluster Innovation Park.

More information about Cancer Crosslinks can be found on the conference website.
Want to know when Cancer Crosslinks 2025 is open for registration? Let us notify you via our newsletter – here is where you sign up.